Reuters logo
BRIEF-Prescient Therapeutics ‍updates on its clinical trials​
May 28, 2017 / 11:18 PM / 4 months ago

BRIEF-Prescient Therapeutics ‍updates on its clinical trials​

May 29 (Reuters) - Prescient Therapeutics Ltd

* ‍updates on its clinical trials with PTX-200 following a serious adverse event in a late-stage patient on its breast cancer trial.​

* subsequent to preliminary safety and efficacy analyses, last patient enrolled in trial experienced a sae and passed away

* ‍ptx has temporarily paused recruitment to each of its PTX-200 trials​

* intends to re-commence enrollment following formal lifting of clinical holds by FDA Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below